Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002124 · ClinicalTrials.gov registry record · Phase 3
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
A Phase 3 study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
NCT00002124: Completed Phase 3 study, sponsored by Pharmacia and Upjohn.
NCT00002124 is a Phase 3 study that has completed, run by Pharmacia and Upjohn. The registered enrollment target is 1,250 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002124, a Phase 3 study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
Study Summary
PART I: To evaluate the safety, tolerance, efficacy, and pharmacokinetics of three fixed doses of delavirdine mesylate (DLV) in combination with zidovudine (AZT) versus AZT alone in HIV-positive patients. PART II: To evaluate the safety, tolerance, efficacy, and pharmacokinetics of ZDV plus 3TC with or without DLV versus ZDV plus DLV in HIV-positive patients.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Delavirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002124
The ClinicalTrials.gov registry entry for NCT00002124 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacia and Upjohn, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002124 about?
NCT00002124 is a clinical study titled "A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3". PART I: To evaluate the safety, tolerance, efficacy, and pharmacokinetics of three fixed doses of delavirdine mesylate (DLV) in combination with zidovudine (AZT) versus AZT alone in HIV-positive patients. PART II: To evaluate the safety, tolerance, efficacy, and pharmacokinetics of ZDV plus 3TC wit...
What is the current status of trial NCT00002124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,250 participants.
What interventions are being tested in trial NCT00002124?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Delavirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002124?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.